Monoprost (Latanoprost)

Latanoprost, the active ingredient in Monoprost, is a prostaglandin analog presented as a unknown strength/unknown form for ocular use. It treats open‑angle glaucoma and ocular hypertension in adults by lowering intra‑ocular pressure.

GNH USA supplies Monoprost as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Monoprost, a prostaglandin analog, is used to lower intra‑ocular pressure in conditions affecting the eye.

Open‑angle glaucoma: reduces intra‑ocular pressure to slow optic‑nerve damage. Ocular hypertension: lowers eye pressure to prevent progression to glaucoma. Pseudoexfoliative glaucoma: helps control pressure in this secondary open‑angle form.

Common Side Effects: - Eye redness or hyperemia - Increased eyelash length and density - Darkening of the iris color - Eye irritation or foreign‑body sensation - Blurred vision shortly after instillation - Mild ocular discomfort

Serious or Rare Side Effects: - Severe allergic reaction (e.g., angio‑edema) - Uveitis or intra‑ocular inflammation - Macular edema, especially in diabetic patients - Paradoxical increase in intra‑ocular pressure - Corneal thinning or ulceration - Persistent ocular pain or vision loss

Before initiating therapy, patients should be evaluated for ocular health and intra‑ocular pressure baseline.

Assess baseline IOP: ensure appropriate monitoring after start. Monitor iris color changes: inform patients of possible permanent darkening. Avoid use in active ocular inflammation: may exacerbate condition. Caution in patients with herpetic eye disease: risk of reactivation. Do not wear contact lenses during treatment: may trap medication. Store at room temperature: keep in original container, protect from moisture and light.

Monoprost may interact with other ocular or systemic agents that affect intra‑ocular pressure.

Major Interactions (Avoid): - Concomitant prostaglandin analog eye drops: risk of excessive pressure reduction. - Systemic non‑steroidal anti‑inflammatory drugs: may blunt prostaglandin effect.

Moderate Interactions (Monitor Closely): - Topical corticosteroids: may diminish hypotensive efficacy. - Beta‑blocker eye drops: additive IOP‑lowering effect, monitor pressure. - Alpha‑agonist eye drops: possible interference with prostaglandin response.